benzylphosphonic acid monosodium salt

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzylphosphonic acid monosodium salt
• 英文别名: Sodium;benzyl(hydroxy)phosphinate
• 化学式: C₇H₈O₃P*Na
• 分子量: 194.102
• InChiKey: BESAEFHCILHDTB-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -2.26
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  60.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  diisopropyl benzylphosphonate 在 三甲基溴硅烷 作用下， 以 1,4-二氧六环 为溶剂， 反应 4.0h， 以88%的产率得到benzylphosphonic acid monosodium salt
  参考文献：
  名称：

  Efficient and Selective Dealkylation of Phosphonate Diisopropyl Esters Using Me3SiBr

  摘要：

  DOI：

  10.1016/00404-0399(50)1334e-

文献信息

• Use of Dendrimers to Stimulate Cell Growth
  申请人：Majoral Jean-Pierre

  公开号：US20090142316A1

  公开（公告）日：2009-06-04

  The present invention relates to the use of dendrimers with monophosphonic or bisphosphonic terminations in order to stimulate the growth of cell cultures or to activate cells in culture.

  本发明涉及在细胞培养中使用具有单磷酸或双磷酸端基的树枝状聚合物，以促进细胞培养的生长或激活细胞。
• TREATMENT APPARATUS
  申请人：Leech Wayne Frederick

  公开号：US20110106053A1

  公开（公告）日：2011-05-05

  A treatment apparatus in the form of a bag which includes a first compartment containing at least one treatment substance, a second compartment containing at least one treatment substance, at least one openable seal between the first and second compartments, wherein at least one treatment substance in the first compartment is incompatible over time with at least one treatment substance in the second compartment.
• US3984501A
  申请人：——

  公开号：US3984501A

  公开（公告）日：1976-10-05
• US8815834B2
  申请人：——

  公开号：US8815834B2

  公开（公告）日：2014-08-26
• [EN] TREATMENT APPARATUS<br/>[FR] APPAREIL DE TRAITEMENT
  申请人：BOMAC RESEARCH LTD

  公开号：WO2009022922A1

  公开（公告）日：2009-02-19

  The present invention relates to a treatment apparatus in the form of a bag which includes a first compartment containing at least one treatment substance, a second compartment containing at least one treatment substance, at least one openable seal between the first and second compartments, characterised in that at least one treatment substance in the first compartment is incompatible over time with at least one treatment substance in the second compartment.